Administration of macrophage colony-stimulating factor mobilized both CD11b+CD11c+ cells and NK1.1+ cells into peripheral blood.
We attempted the phenotypic characterization of peripheral blood (PB) cells after daily administration of macrophage colony-stimulating factor (M-CSF) in mice. The number of CD11b+ cells was increased by M-CSF treatment (2- and 5-day injections). Notably, CD11bbrightCD11cdim, CD11b+CD11c+ and CD11b+CD80+ cells were significantly increased by 2-day treatment of M-CSF. On the other hand, the number of NK1.1+ cells was not changed by the 2-day treatment, but it was significantly increased by the 5-day treatment. However, the numbers of CD3+ and NK1.1+CD3+ cells were not changed by M-CSF treatment. Then, mononuclear cells (MNCs) were separated from the PB of mice treated with saline or M-CSF, and they were incubated with GM-CSF + IL-4 or IL-2. Compared with the saline-treated one (S-MNCs), the MNCs of M-CSF-treated mice (M-MNCs) showed strong proliferation by the GM-CSF + IL-4 stimulation. The MNCs could stimulate proliferation of allo-T cells in the mixed lymphocyte reaction (MLR), especially the M-MNCs showed strong reaction. On the other hand, the stimulation by IL-2 induced strong cell growth of MNCs. And M-CSF treatment enhanced this response. Furthermore, the M-MNCs (stimulated by IL-2 in vitro) exhibited greater cytotoxicity against Yac-1 cells than the S-MNCs. In conclusion, we found that administration of M-CSF mobilized CD11b+, CD11b+CD11c+, CD11b+CD80+, and NK1.1+cells into PB. And the injection of M-CSF facilitates the generation of dendritic and natural killer cells from PB cells in vitro. These results suggest that the mobilized cells may provide for application of immunotherapy.
Misawa
Eriko
E
Biochemical Research Laboratory, Morinaga Milk Industry Co. Ltd., Higashihara 5-1-83, Zama, Kanagawa 228-8583, Japan. e_misawa@morinagamilk.co.jp
Sakurai
Takuma
T
Yamada
Muneo
M
Tamura
Yoshitaka
Y
Motoyoshi
Kazuo
K
D000818:Animals; D000941:Antigens / Q000378:metabolism*; D000950:Antigens, Ly; D000954:Antigens, Surface; D018122:B7-1 Antigen / Q000378:metabolism; D039481:CD11b Antigen / Q000378:metabolism*; D039521:CD11c Antigen / Q000378:metabolism*; D017252:CD3 Complex / Q000378:metabolism; D003115:Colony-Stimulating Factors / Q000494:pharmacology; D016207:Cytokines / Q000096:biosynthesis; D003713:Dendritic Cells / Q000187:drug effects / Q000378:metabolism; D007694:Killer Cells, Natural / Q000187:drug effects / Q000378:metabolism*; D037181:Lectins, C-Type; D007959:Lymphocyte Culture Test, Mixed; D016173:Macrophage Colony-Stimulating Factor / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D055651:NK Cell Lectin-Like Receptor Subfamily B; D010641:Phenotype; D011506:Proteins / Q000378:metabolism*; D011994:Recombinant Proteins
D000941:Antigens; D000950:Antigens, Ly; D000954:Antigens, Surface; D018122:B7-1 Antigen; D039481:CD11b Antigen; D039521:CD11c Antigen; D017252:CD3 Complex; D003115:Colony-Stimulating Factors; D016207:Cytokines; C527211:Klrb1c protein, mouse; D037181:Lectins, C-Type; D055651:NK Cell Lectin-Like Receptor Subfamily B; D011506:Proteins; D011994:Recombinant Proteins; D016173:Macrophage Colony-Stimulating Factor